|
| In order to survive a disaster or other business shut down, biotechnology companies need to combine their insurance portfolio with an effective disaster-recovery plan that will serve as a road map, providing directions the company will take if a catastrophe or other business interruption strikes. |
| Read More... |
| |
|
| To help health executives and policy makers anticipate and prepare for what's ahead, PricewaterhouseCoopers' Health Research Institute has identified the Top Eight Health Industry Issues in 2008. |
| Read More... |
| |
|
| In today's volatile climate of increased regulatory oversight, media scrutiny and widespread recalls, even the hint of a product's failure or a procedural error is enough to damage a company's reputation and negatively impact its bottom line. Life Science companies are especially vulnerable to these risks given the nature of their products and the intense regulatory burdens under which they operate. Failure to meet government and industry regulations can result in punitive events, namely audits, fines, warnings and lawsuits, that adversely affect a company's productivity and ability to conduct business. Special attention has been given to Corrective and Preventive Action (CAPA) violations in recent years. This white paper by Pilgrim Software points out that quality systems must encompass the majority of their company's processes in compliance with CAPA. |
| Read More... |
| |
RSS